Effects of treatment
    Author: JC Holzer and DM Bear

    Antiepileptic drugs

    Positive psychotropic properties

    Certain antiepileptic drugs (AEDs) have positive psychotropic properties, as listed on the table below. On the other hand, AEDs also can have negative psychotropic properties that produce a variety of psychiatric symptoms. Psychiatric adverse events thus can result from:

    • the discontinuation of an AED with positive psychotropic properties (in patients with a prior mood disorder that had been kept in remission with the AED)
    • the addition of an AED with negative psychotropic properties

    AEDs with positive psychotropic properties*
    Bipolar Disorder Social phobia Panic Psychosis(allows lower dose of antipsychotic)
    Antimanic Antidepressant Prophylactic
    CBZ LTG CBZ gabapentin VPA VPA
    VPA VPA clonazepam
    LTG
    *Proven in double-blind, placebo-controlled studies.
    CBZ = carbamazepine; LTG = lamotrigine; VPA = valproic acid

    Psychiatric adverse events

    The following table summarizes the types of psychiatric adverse events reported with the use of AEDs. It should be noted that an AED with positive psychotropic properties can still cause psychiatric adverse events.

    Psychiatric adverse events related to AEDs
    AED ADHD Behavior disorders Mood disorders Anxiety disorders Psychosis Forced normalization
    Benzodiaze-
    pines
    + + + - + -
    Carba-
    mazepine
    - + + - - +
    Ethosuximide - + + - + +
    Felbamate - + + - - +
    Gabapentin - + + - - -
    Lamotrigine - + - + + -
    Levetiracetam + + + - + +
    Oxcarbazepine - - - - - -
    Phenobarbital/
    primidone
    + + + + + +
    Phenytoin - + - - - +
    Tiagabine - + + - - -
    Topiramate + + + - + +
    Valproic acid - + - - + +
    Zonisamide - + + - - -
    AED = antiepileptic drug; ADHD = attention deficit hyperactivity disorder.

    It is important to investigate the psychiatric history of the patient and his or her family, as some AEDs can cause psychiatric adverse events specifically in patients with such risks. For example, phenobarbital has been found to cause symptoms of depression more often in patients with family history of this mood disorder.

    Epilepsy surgery

    Patients may be considered for temporal lobectomy if their seizures are medication-refractory, if their symptoms significantly interfere with the ability to lead a productive life, and if a resectable seizure focus is identified. Most patients who undergo the procedure have a substantial decrease in their seizures and many become seizure-free. Positive outcomes include increased productivity and an improvement in social functioning and cognition.

    Psychiatric complications after temporal lobectomy have been identified, however. These can be divided into several categories:

    • symptoms of mood lability, dysphoria, and anxiety noted during the first 6 to 12 weeks after surgery - these symptoms tend to remit by the sixth month
    • de novo depressive disorders
    • de novo psychotic disorders
    • exacerbation or recurrence of depressive disorders that existed prior to surgery

    Postsurgical depressive disorders can be seen in about 30% to 40% of patients who undergo a temporal lobectomy. Most are transient and remit spontaneously or with antidepressant medication.

    De novo depressive disorders usually occur during the first 12 months after surgery and respond to antidepressant medication. It is important to recognize them, as some can be severe enough to cause suicide attempts. A timely and effective intervention may prevent such complications. These depressive episodes can occur both in patients who become seizure-free and in those with persistent seizures after surgery.

    De novo psychotic episodes are relatively rare. They are more likely in patients who undergo temporal lobe resections that included certain types of benign tumors. Antipsychotic medications must be used.

    Exacerbation or recurrence of prior depressive disorders requires the reintroduction of antidepressant medication or adjustment of the dose if the patient is already taking one.

    Whether epilepsy surgery should be recommended to patients with a psychotic disorder has been controversial. I believe that surgery can be offered to these patients if they clearly understand the risks and potential benefits of the surgery and the nature of the presurgical evaluation, and can cooperate with all the tests. Recent reports, in fact, have shown that the management of the psychotic disorder can be greatly facilitated when seizures are under control after epilepsy surgery.

    Interictal behavioral symptoms often do not change with surgery.

    Vagus nerve stimulator (VNS)

    The vagus nerve stimulator, approved for use in the United States in 1997, is a pacemaker-like device that sends electrical stimuli to the brain through the vagus nerve in the neck. Besides seizure control for some people with epilepsy, this device also has been found to have positive psychotropic properties:

    • antidepressant effect
    • antianxiety effect
    • shortening of the postictal period, facilitating the recovery from a seizure and preventing or limiting the duration of postictal psychiatric symptoms.

    Reviewed and revised April 2004 by Andres M. Kanner, M.D., epilepsy.com Editorial Board.

     

    Back to top